In the last 12 months, insiders at QUEST DIAGNOSTICS INC ($DGX) filed 370 transactions with the SEC: 0 open-market purchases totaling $0 and 86 sales totaling $67,243,982. Net insider sentiment: net selling.
QUEST DIAGNOSTICS INC operates in the Services-medical laboratories industry (Industrial Applications and Services sector).
Most Active Insiders
- Davis J. E. (CEO and President) — 43 transactions totaling $64,509,921
- PREVOZNIK MICHAEL E (SVP & General Counsel) — 48 transactions totaling $34,447,694
- Doherty Catherine T. (EVP, Regional Businesses) — 40 transactions totaling $29,687,668
- Plewman Patrick (SVP for Diagnostic Services) — 47 transactions totaling $10,041,359
- SAMAD SAM (Executive Vice President & CFO) — 27 transactions totaling $9,930,221
View all SEC Filings for QUEST DIAGNOSTICS INC (DGX).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| April 1, 2026 | WENTWORTH TIMOTHY C | Director | A | Phantom Stock Units | 198 | $0.00 | 198.0000 | 111,000,000 | 9999.99% | 0.00% |
| March 9, 2026 | WENTWORTH TIMOTHY C | Director | A | Common Stock | 215 | $0.00 | 215.0000 | 111,000,000 | 9999.99% | 0.00% |
| March 5, 2026 | Doherty Catherine T. | EVP, Regional Businesses | S | Common Stock | 5558 | $206.21 | 71,624.0000 | 111,000,000 | 7.20% | 0.01% |
| March 4, 2026 | SAMAD SAM | Executive Vice President & CFO | A | Common Stock | 13947 | $204.86 | 40,988.0000 | 111,000,000 | 51.58% | 0.01% |
| March 4, 2026 | SAMAD SAM | Executive Vice President & CFO | F | Common Stock | 7720 | $204.86 | 33,268.0000 | 111,000,000 | 18.83% | 0.01% |
| March 4, 2026 | Doherty Catherine T. | EVP, Regional Businesses | A | Common Stock | 11364 | $204.86 | 82,988.0000 | 111,000,000 | 15.87% | 0.01% |
| March 4, 2026 | Doherty Catherine T. | EVP, Regional Businesses | F | Common Stock | 5806 | $204.86 | 77,182.0000 | 111,000,000 | 7.00% | 0.01% |
| March 4, 2026 | Deppe Michael J | SVP, Corp. Controller & CAO | F | Common Stock | 750 | $204.86 | 35,196.0000 | 111,000,000 | 2.09% | 0.00% |
| March 4, 2026 | Deppe Michael J | SVP, Corp. Controller & CAO | A | Common Stock | 1473 | $204.86 | 35,946.0000 | 111,000,000 | 4.27% | 0.00% |
| March 5, 2026 | Plewman Patrick | SVP for Diagnostic Services | S | Common Stock | 2855 | $206.21 | 15,198.0000 | 111,000,000 | 15.81% | 0.00% |
| March 4, 2026 | Plewman Patrick | SVP for Diagnostic Services | F | Common Stock | 2827 | $204.86 | 18,053.0000 | 111,000,000 | 13.54% | 0.00% |
| March 4, 2026 | Plewman Patrick | SVP for Diagnostic Services | A | Common Stock | 5682 | $204.86 | 20,880.0000 | 111,000,000 | 37.39% | 0.01% |
| March 4, 2026 | Davis J. E. | CEO and President | F | Common Stock | 26414 | $204.86 | 142,423.0000 | 111,000,000 | 15.64% | 0.02% |
| March 4, 2026 | Davis J. E. | CEO and President | A | Common Stock | 51652 | $204.86 | 168,837.0000 | 111,000,000 | 44.08% | 0.05% |
| March 5, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | Common Stock | 3878 | $206.21 | 43,294.0000 | 111,000,000 | 8.22% | 0.00% |
| March 4, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | F | Common Stock | 3354 | $204.86 | 47,172.0000 | 111,000,000 | 6.64% | 0.00% |
| March 4, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | A | Common Stock | 7232 | $204.86 | 50,526.0000 | 111,000,000 | 16.70% | 0.01% |
| March 4, 2026 | DELANEY MARK E | SVP & Chief Commercial Officer | F | Common Stock | 2326 | $204.86 | 11,864.0000 | 111,000,000 | 16.39% | 0.00% |
| March 4, 2026 | DELANEY MARK E | SVP & Chief Commercial Officer | A | Common Stock | 5682 | $204.86 | 14,190.0000 | 111,000,000 | 66.78% | 0.01% |
| March 4, 2026 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S | Common Stock | 2628 | $204.86 | 15,457.0000 | 111,000,000 | 14.53% | 0.00% |
| March 4, 2026 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A | Common Stock | 6200 | $204.86 | 18,085.0000 | 111,000,000 | 52.17% | 0.01% |
| March 2, 2026 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | F | Common Stock | 205 | $204.86 | 11,885.0000 | 111,000,000 | 1.70% | 0.00% |
| March 2, 2026 | Doherty Catherine T. | EVP, Regional Businesses | F | Common Stock | 648 | $204.86 | 72,256.0000 | 111,000,000 | 0.89% | 0.00% |
| March 3, 2026 | Doherty Catherine T. | EVP, Regional Businesses | S | Common Stock | 632 | $207.73 | 71,624.0000 | 111,000,000 | 0.87% | 0.00% |
| March 2, 2026 | SAMAD SAM | Executive Vice President & CFO | F | Common Stock | 869 | $204.86 | 27,041.0000 | 111,000,000 | 3.11% | 0.00% |
| March 2, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | F | Common Stock | 288 | $204.86 | 43,820.0000 | 111,000,000 | 0.65% | 0.00% |
| March 3, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | Common Stock | 526 | $207.73 | 43,294.0000 | 111,000,000 | 1.20% | 0.00% |
| March 2, 2026 | Davis J. E. | CEO and President | F | Common Stock | 2968 | $204.86 | 127,185.0000 | 111,000,000 | 2.28% | 0.00% |
| March 2, 2026 | Davis J. E. | CEO and President | S | Common Stock | 10000 | $212.52 | 117,185.0000 | 111,000,000 | 7.86% | 0.01% |
| March 2, 2026 | Plewman Patrick | SVP for Diagnostic Services | F | Common Stock | 230 | $204.86 | 15,608.0000 | 111,000,000 | 1.45% | 0.00% |
| March 3, 2026 | Plewman Patrick | SVP for Diagnostic Services | S | Common Stock | 410 | $207.73 | 15,198.0000 | 111,000,000 | 2.63% | 0.00% |
| March 2, 2026 | Deppe Michael J | SVP, Corp. Controller & CAO | F | Common Stock | 88 | $204.86 | 35,179.0000 | 111,000,000 | 0.25% | 0.00% |
| March 2, 2026 | DELANEY MARK E | SVP & Chief Commercial Officer | F | Common Stock | 188 | $204.86 | 8,508.0000 | 111,000,000 | 2.16% | 0.00% |
| Feb. 18, 2026 | DELANEY MARK E | SVP & Chief Commercial Officer | A | Non-Qualifed Stock Option (right to buy) | 7332 | $0.00 | 7,332.0000 | 111,000,000 | 9999.99% | 0.01% |
| Feb. 18, 2026 | Deppe Michael J | SVP, Corp. Controller & CAO | A | Common Stock | 366 | $0.00 | 35,448.0000 | 111,000,000 | 1.04% | 0.00% |
| Feb. 18, 2026 | Deppe Michael J | SVP, Corp. Controller & CAO | F | Common Stock | 83 | $210.01 | 35,365.0000 | 111,000,000 | 0.23% | 0.00% |
| Feb. 18, 2026 | Deppe Michael J | SVP, Corp. Controller & CAO | F | Common Stock | 99 | $206.99 | 35,266.0000 | 111,000,000 | 0.28% | 0.00% |
| Feb. 18, 2026 | Deppe Michael J | SVP, Corp. Controller & CAO | A | Non-Qualifed Stock Option (right to buy) | 1688 | $0.00 | 1,688.0000 | 111,000,000 | 9999.99% | 0.00% |
| Jan. 28, 2026 | Lassiter Wright III | Director | L | Common Stock | 7 | $183.51 | 9,057.0000 | 111,000,000 | 0.08% | 0.00% |
| Jan. 28, 2026 | CARTER ROBERT B | Director | L | Common Stock | 6 | $183.51 | 2,704.0000 | 111,000,000 | 0.22% | 0.00% |
| Jan. 28, 2026 | Gregg Vicky B | Director | L | Common Stock | 67 | $183.51 | 17,104.0000 | 111,000,000 | 0.39% | 0.00% |
| Jan. 28, 2026 | DELANEY MARK E | SVP & Chief Commercial Officer | L | Common Stock | 15 | $183.51 | 8,696.0000 | 111,000,000 | 0.17% | 0.00% |
| Feb. 18, 2026 | SAMAD SAM | Executive Vice President & CFO | A | Common Stock | 3965 | $0.00 | 29,706.0000 | 111,000,000 | 15.40% | 0.00% |
| Feb. 18, 2026 | SAMAD SAM | Executive Vice President & CFO | F | Common Stock | 855 | $210.01 | 28,851.0000 | 111,000,000 | 2.88% | 0.00% |
| Feb. 18, 2026 | SAMAD SAM | Executive Vice President & CFO | F | Common Stock | 1010 | $206.99 | 27,841.0000 | 111,000,000 | 3.50% | 0.00% |
| Jan. 28, 2026 | SAMAD SAM | Executive Vice President & CFO | A | Common Stock | 69 | $183.51 | 27,910.0000 | 111,000,000 | 0.25% | 0.00% |
| Feb. 18, 2026 | SAMAD SAM | Executive Vice President & CFO | A | Non-Qualifed Stock Option (right to buy) | 18303 | $0.00 | 18,303.0000 | 111,000,000 | 9999.99% | 0.02% |
| Feb. 18, 2026 | Plewman Patrick | SVP for Diagnostic Services | A | Common Stock | 1952 | $0.00 | 17,333.0000 | 111,000,000 | 12.69% | 0.00% |
| Feb. 18, 2026 | Plewman Patrick | SVP for Diagnostic Services | F | Common Stock | 244 | $210.01 | 17,089.0000 | 111,000,000 | 1.41% | 0.00% |
| Feb. 18, 2026 | Plewman Patrick | SVP for Diagnostic Services | F | Common Stock | 293 | $206.99 | 16,796.0000 | 111,000,000 | 1.71% | 0.00% |
| Feb. 19, 2026 | Plewman Patrick | SVP for Diagnostic Services | S | Common Stock | 958 | $204.83 | 15,838.0000 | 111,000,000 | 5.70% | 0.00% |
| Feb. 18, 2026 | Plewman Patrick | SVP for Diagnostic Services | A | Non-Qualifed Stock Option (right to buy) | 9009 | $0.00 | 9,009.0000 | 111,000,000 | 9999.99% | 0.01% |
| Feb. 18, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | A | Common Stock | 2013 | $0.00 | 45,868.0000 | 111,000,000 | 4.59% | 0.00% |
| Feb. 18, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | F | Common Stock | 301 | $210.01 | 45,567.0000 | 111,000,000 | 0.66% | 0.00% |
| Feb. 18, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | F | Common Stock | 347 | $206.99 | 45,220.0000 | 111,000,000 | 0.76% | 0.00% |
| Feb. 19, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | Common Stock | 1111 | $204.83 | 44,109.0000 | 111,000,000 | 2.46% | 0.00% |
| Feb. 18, 2026 | PREVOZNIK MICHAEL E | SVP & General Counsel | A | Non-Qualifed Stock Option (right to buy) | 9289 | $0.00 | 9,289.0000 | 111,000,000 | 9999.99% | 0.01% |
| Feb. 18, 2026 | Davis J. E. | CEO and President | A | Common Stock | 15857 | $0.00 | 136,337.0000 | 111,000,000 | 13.16% | 0.01% |
| Feb. 18, 2026 | Davis J. E. | CEO and President | F | Common Stock | 2396 | $210.01 | 133,941.0000 | 111,000,000 | 1.76% | 0.00% |
| Feb. 18, 2026 | Davis J. E. | CEO and President | F | Common Stock | 3788 | $206.99 | 130,153.0000 | 111,000,000 | 2.83% | 0.00% |
| Feb. 18, 2026 | Davis J. E. | CEO and President | A | Non-Qualifed Stock Option (right to buy) | 73225 | $0.00 | 73,225.0000 | 111,000,000 | 9999.99% | 0.07% |
| Feb. 18, 2026 | Doherty Catherine T. | EVP, Regional Businesses | A | Common Stock | 2928 | $0.00 | 75,499.0000 | 111,000,000 | 4.03% | 0.00% |
| Feb. 18, 2026 | Doherty Catherine T. | EVP, Regional Businesses | F | Common Stock | 433 | $210.01 | 75,066.0000 | 111,000,000 | 0.57% | 0.00% |
| Feb. 18, 2026 | Doherty Catherine T. | EVP, Regional Businesses | F | Common Stock | 728 | $206.99 | 74,338.0000 | 111,000,000 | 0.97% | 0.00% |
| Feb. 19, 2026 | Doherty Catherine T. | EVP, Regional Businesses | S | Common Stock | 1433 | $204.83 | 72,905.0000 | 111,000,000 | 1.93% | 0.00% |
| Feb. 18, 2026 | Doherty Catherine T. | EVP, Regional Businesses | A | Non-Qualifed Stock Option (right to buy) | 13514 | $0.00 | 13,514.0000 | 111,000,000 | 9999.99% | 0.01% |
| Feb. 18, 2026 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | F | Common Stock | 252 | $210.01 | 10,186.0000 | 111,000,000 | 2.41% | 0.00% |
| Feb. 18, 2026 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | F | Common Stock | 259 | $206.99 | 9,927.0000 | 111,000,000 | 2.54% | 0.00% |
| Feb. 18, 2026 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A | Common Stock | 2135 | $0.00 | 12,062.0000 | 111,000,000 | 21.51% | 0.00% |
| Jan. 28, 2026 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | L | Common Stock | 16 | $183.52 | 12,078.0000 | 111,000,000 | 0.13% | 0.00% |
| Feb. 18, 2026 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A | Non-Qualifed Stock Option (right to buy) | 9853 | $0.00 | 9,853.0000 | 111,000,000 | 9999.99% | 0.01% |
| Feb. 18, 2026 | DELANEY MARK E | SVP & Chief Commercial Officer | A | Common Stock | 1586 | $0.00 | 9,116.0000 | 111,000,000 | 21.06% | 0.00% |
| Feb. 18, 2026 | DELANEY MARK E | SVP & Chief Commercial Officer | F | Common Stock | 205 | $210.01 | 8,911.0000 | 111,000,000 | 2.25% | 0.00% |
| Feb. 18, 2026 | DELANEY MARK E | SVP & Chief Commercial Officer | F | Common Stock | 230 | $206.99 | 8,681.0000 | 111,000,000 | 2.58% | 0.00% |
| Feb. 13, 2026 | Doherty Catherine T. | EVP, Regional Businesses | M | Non-Qualifed Stock Option (right to buy) | 26165 | $112.17 | 0.0000 | 111,000,000 | 100.00% | 0.02% |
| Feb. 13, 2026 | Doherty Catherine T. | EVP, Regional Businesses | S | Common Stock | 351 | $209.10 | 72,571.0000 | 111,000,000 | 0.48% | 0.00% |
| Feb. 13, 2026 | Doherty Catherine T. | EVP, Regional Businesses | S | Common Stock | 1619 | $208.21 | 72,922.0000 | 111,000,000 | 2.17% | 0.00% |
| Feb. 13, 2026 | Doherty Catherine T. | EVP, Regional Businesses | S | Common Stock | 3500 | $207.08 | 74,541.0000 | 111,000,000 | 4.48% | 0.00% |
| Feb. 13, 2026 | Doherty Catherine T. | EVP, Regional Businesses | S | Common Stock | 10122 | $206.37 | 78,041.0000 | 111,000,000 | 11.48% | 0.01% |
| Feb. 13, 2026 | Doherty Catherine T. | EVP, Regional Businesses | S | Common Stock | 10573 | $205.21 | 88,163.0000 | 111,000,000 | 10.71% | 0.01% |
| Feb. 13, 2026 | Doherty Catherine T. | EVP, Regional Businesses | M | Common Stock | 26165 | $112.17 | 98,736.0000 | 111,000,000 | 36.05% | 0.02% |
| Feb. 10, 2026 | Plewman Patrick | SVP for Diagnostic Services | M | Non-Qualifed Stock Option (right to buy) | 5662 | $121.81 | 0.0000 | 111,000,000 | 100.00% | 0.01% |
| Feb. 10, 2026 | Plewman Patrick | SVP for Diagnostic Services | S | Common Stock | 5662 | $204.00 | 15,381.0000 | 111,000,000 | 26.91% | 0.01% |
| Feb. 10, 2026 | Plewman Patrick | SVP for Diagnostic Services | M | Common Stock | 5662 | $121.81 | 21,043.0000 | 111,000,000 | 36.81% | 0.01% |
| Jan. 28, 2026 | Plewman Patrick | SVP for Diagnostic Services | A | Common Stock | 48 | $183.51 | 15,381.0000 | 111,000,000 | 0.31% | 0.00% |
| Nov. 25, 2025 | Gregg Vicky B | Director | S | Common Stock | 1250 | $191.76 | 17,037.0000 | 111,000,000 | 6.84% | 0.00% |
| Nov. 25, 2025 | Davis J. E. | CEO and President | M | Common Stock | 55093 | $95.80 | 175,573.0000 | 111,000,000 | 45.73% | 0.05% |
| Nov. 25, 2025 | Davis J. E. | CEO and President | S | Common Stock | 9342 | $191.59 | 166,231.0000 | 111,000,000 | 5.32% | 0.01% |
| Nov. 25, 2025 | Davis J. E. | CEO and President | S | Common Stock | 41004 | $192.27 | 125,227.0000 | 111,000,000 | 24.67% | 0.04% |
| Nov. 25, 2025 | Davis J. E. | CEO and President | S | Common Stock | 4747 | $192.97 | 120,480.0000 | 111,000,000 | 3.79% | 0.00% |
| Nov. 25, 2025 | Davis J. E. | CEO and President | M | Non-Qualifed Stock Option (right to buy) | 55093 | $95.80 | 0.0000 | 111,000,000 | 100.00% | 0.05% |
| Nov. 18, 2025 | DELANEY MARK E | SVP & Chief Commercial Officer | M | Non-Qualifed Stock Option (right to buy) | 7846 | $144.47 | 0.0000 | 111,000,000 | 100.00% | 0.01% |
| Nov. 18, 2025 | DELANEY MARK E | SVP & Chief Commercial Officer | M | Common Stock | 7846 | $144.47 | 15,376.0000 | 111,000,000 | 104.20% | 0.01% |
| Nov. 18, 2025 | DELANEY MARK E | SVP & Chief Commercial Officer | M | Common Stock | 100 | $143.33 | 15,476.0000 | 111,000,000 | 0.65% | 0.00% |
| Nov. 18, 2025 | DELANEY MARK E | SVP & Chief Commercial Officer | S | Common Stock | 7946 | $187.35 | 7,530.0000 | 111,000,000 | 51.34% | 0.01% |
| Nov. 18, 2025 | DELANEY MARK E | SVP & Chief Commercial Officer | M | Non-Qualifed Stock Option (right to buy) | 100 | $143.33 | 7,484.0000 | 111,000,000 | 1.32% | 0.00% |
| Nov. 5, 2025 | Davis J. E. | CEO and President | F | Common Stock | 7143 | $175.57 | 120,480.0000 | 111,000,000 | 5.60% | 0.01% |
| Oct. 21, 2025 | SAMAD SAM | Executive Vice President & CFO | A | Common Stock | 68 | $189.08 | 25,741.0000 | 111,000,000 | 0.26% | 0.00% |
| Oct. 21, 2025 | DELANEY MARK E | SVP & Chief Commercial Officer | A | Common Stock | 15 | $189.08 | 7,530.0000 | 111,000,000 | 0.20% | 0.00% |
| Oct. 21, 2025 | CARTER ROBERT B | Director | A | Common Stock | 6 | $189.09 | 2,698.0000 | 111,000,000 | 0.22% | 0.00% |
| Oct. 22, 2025 | PFEIFFER GARY M | Director | S | Common Stock | 1482 | $182.40 | 29,431.0000 | 111,000,000 | 4.79% | 0.00% |
| Oct. 23, 2025 | PFEIFFER GARY M | Director | I | Phantom Stock | 4413 | $190.58 | 0.0000 | 111,000,000 | 100.00% | 0.00% |
| Oct. 21, 2025 | Gregg Vicky B | Director | A | Common Stock | 70 | $189.08 | 18,287.0000 | 111,000,000 | 0.38% | 0.00% |
| Oct. 21, 2025 | Plewman Patrick | SVP for Diagnostic Services | A | Common Stock | 46 | $189.08 | 15,333.0000 | 111,000,000 | 0.30% | 0.00% |
| Oct. 21, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A | Common Stock | 15 | $189.08 | 10,372.0000 | 111,000,000 | 0.14% | 0.00% |
| Oct. 1, 2025 | Lassiter Wright III | Director | A | Phantom Stock Units | 157 | $0.00 | 678.7770 | 111,000,000 | 30.09% | 0.00% |
| Oct. 1, 2025 | RING TIMOTHY M | Director | A | Phantom Stock Units | 233 | $0.00 | 17,036.4950 | 111,000,000 | 1.39% | 0.00% |
| Sept. 26, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | Common Stock | 83 | $187.22 | 43,953.0000 | 112,000,000 | 0.19% | 0.00% |
| Sept. 26, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | M | Common Stock | 227 | $103.57 | 44,036.0000 | 112,000,000 | 0.52% | 0.00% |
| Sept. 26, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | M | Non-Qualifed Stock Option (right to buy) | 227 | $103.57 | 0.0000 | 112,000,000 | 100.00% | 0.00% |
| Sept. 26, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | Common Stock | 144 | $188.66 | 43,809.0000 | 112,000,000 | 0.33% | 0.00% |
| Sept. 24, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | M | Common Stock | 175 | $103.57 | 43,983.0000 | 112,000,000 | 0.40% | 0.00% |
| Sept. 24, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | Common Stock | 175 | $187.02 | 43,808.0000 | 112,000,000 | 0.40% | 0.00% |
| Sept. 23, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | Common Stock | 28288 | $187.12 | 43,808.0000 | 112,000,000 | 39.24% | 0.03% |
| Sept. 23, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | M | Non-Qualifed Stock Option (right to buy) | 28288 | $103.57 | 402.0000 | 112,000,000 | 98.60% | 0.03% |
| Sept. 23, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | M | Common Stock | 28288 | $103.57 | 72,096.0000 | 112,000,000 | 64.57% | 0.03% |
| Sept. 24, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | M | Non-Qualifed Stock Option (right to buy) | 175 | $103.57 | 227.0000 | 112,000,000 | 43.53% | 0.00% |
| Aug. 21, 2025 | Plewman Patrick | SVP for Diagnostic Services | S | Common Stock | 1975 | $185.00 | 15,269.0000 | 112,000,000 | 11.45% | 0.00% |
| Aug. 19, 2025 | Plewman Patrick | SVP for Diagnostic Services | S | Common Stock | 4532 | $183.00 | 17,244.0000 | 112,000,000 | 20.81% | 0.00% |
| Aug. 19, 2025 | Plewman Patrick | SVP for Diagnostic Services | M | Common Stock | 4532 | $112.17 | 21,776.0000 | 112,000,000 | 26.28% | 0.00% |
| Aug. 19, 2025 | Plewman Patrick | SVP for Diagnostic Services | M | Non-Qualifed Stock Option (right to buy) | 4532 | $112.17 | 0.0000 | 112,000,000 | 100.00% | 0.00% |
| Aug. 15, 2025 | Plewman Patrick | SVP for Diagnostic Services | S | Common Stock | 1975 | $180.00 | 17,244.0000 | 112,000,000 | 10.28% | 0.00% |
| Aug. 13, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | F | Common Stock | 123 | $175.91 | 10,324.0000 | 112,000,000 | 1.18% | 0.00% |
| Aug. 6, 2025 | Plewman Patrick | SVP for Diagnostic Services | S | Common Stock | 1975 | $175.00 | 19,219.0000 | 112,000,000 | 9.32% | 0.00% |
| Aug. 6, 2025 | Plewman Patrick | SVP for Diagnostic Services | S | Common Stock | 3560 | $175.00 | 21,185.0000 | 112,000,000 | 14.39% | 0.00% |
| Aug. 6, 2025 | Plewman Patrick | SVP for Diagnostic Services | M | Common Stock | 3560 | $86.63 | 24,745.0000 | 112,000,000 | 16.80% | 0.00% |
| Aug. 6, 2025 | Plewman Patrick | SVP for Diagnostic Services | M | Non-Qualifed Stock Option (right to buy) | 3560 | $86.63 | 0.0000 | 112,000,000 | 100.00% | 0.00% |
| July 30, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S | Common Stock | 5224 | $167.40 | 12,647.0000 | 112,000,000 | 29.23% | 0.00% |
| July 30, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | M | Common Stock | 5224 | $112.17 | 17,871.0000 | 112,000,000 | 41.31% | 0.00% |
| July 30, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S | Common Stock | 3045 | $167.40 | 12,647.0000 | 112,000,000 | 19.40% | 0.00% |
| July 30, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | M | Common Stock | 3045 | $86.63 | 15,692.0000 | 112,000,000 | 24.08% | 0.00% |
| July 30, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | M | Non-Qualifed Stock Option (right to buy) | 5224 | $112.17 | 0.0000 | 112,000,000 | 100.00% | 0.00% |
| July 30, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | M | Non-Qualifed Stock Option (right to buy) | 3045 | $86.63 | 0.0000 | 112,000,000 | 100.00% | 0.00% |
| July 31, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S | Common Stock | 2210 | $170.00 | 10,437.0000 | 112,000,000 | 17.47% | 0.00% |
| July 21, 2025 | Lassiter Wright III | Director | L | Common Stock | 7 | $167.51 | 9,044.0000 | 112,000,000 | 0.08% | 0.00% |
| July 21, 2025 | Gregg Vicky B | Director | L | Common Stock | 79 | $167.50 | 18,217.0000 | 112,000,000 | 0.44% | 0.00% |
| July 21, 2025 | DELANEY MARK E | SVP & Chief Commercial Officer | L | Common Stock | 17 | $167.49 | 7,515.0000 | 112,000,000 | 0.23% | 0.00% |
| July 21, 2025 | CARTER ROBERT B | Director | L | Common Stock | 7 | $167.51 | 2,692.0000 | 112,000,000 | 0.26% | 0.00% |
| July 21, 2025 | SAMAD SAM | Executive Vice President & CFO | L | Common Stock | 72 | $167.50 | 25,673.0000 | 112,000,000 | 0.28% | 0.00% |
| July 21, 2025 | Plewman Patrick | SVP for Diagnostic Services | L | Common Stock | 80 | $167.49 | 21,185.0000 | 112,000,000 | 0.38% | 0.00% |
| July 21, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | L | Common Stock | 27 | $167.50 | 12,647.0000 | 112,000,000 | 0.21% | 0.00% |
| July 16, 2025 | SAMAD SAM | Executive Vice President & CFO | F | Common Stock | 850 | $169.01 | 25,601.0000 | 112,000,000 | 3.21% | 0.00% |
| July 1, 2025 | Lassiter Wright III | Director | A | Phantom Stock Units | 160 | $0.00 | 520.8540 | 112,000,000 | 44.34% | 0.00% |
| July 1, 2025 | RING TIMOTHY M | Director | A | Phantom Stock Units | 236 | $0.00 | 16,725.3780 | 112,000,000 | 1.43% | 0.00% |
| May 15, 2025 | Doi Tracey | Director | A | Common Stock | 1203 | $0.00 | 6,490.0000 | 111,000,000 | 22.75% | 0.00% |
| May 15, 2025 | MAIN TIMOTHY L | Director | A | Common Stock | 1203 | $0.00 | 26,297.0000 | 111,000,000 | 4.79% | 0.00% |
| May 15, 2025 | MORRISON DENISE M | Director | A | Common Stock | 1203 | $0.00 | 10,742.0000 | 111,000,000 | 12.61% | 0.00% |
| May 15, 2025 | Lassiter Wright III | Director | A | Common Stock | 1203 | $0.00 | 9,037.0000 | 111,000,000 | 15.36% | 0.00% |
| May 15, 2025 | RING TIMOTHY M | Director | A | Common Stock | 1203 | $0.00 | 29,507.0000 | 111,000,000 | 4.25% | 0.00% |
| May 15, 2025 | PFEIFFER GARY M | Director | A | Common Stock | 1203 | $0.00 | 30,669.0000 | 111,000,000 | 4.08% | 0.00% |
| May 15, 2025 | CARTER ROBERT B | Director | A | Common Stock | 1203 | $0.00 | 2,685.0000 | 111,000,000 | 81.17% | 0.00% |
| May 15, 2025 | Diaz Luis | Director | A | Common Stock | 1203 | $0.00 | 4,054.0000 | 111,000,000 | 42.20% | 0.00% |
| May 15, 2025 | Gregg Vicky B | Director | A | Common Stock | 1203 | $0.00 | 18,138.0000 | 111,000,000 | 7.10% | 0.00% |
| May 13, 2025 | DELANEY MARK E | SVP & Chief Commercial Officer | S | Common Stock | 874 | $175.31 | 7,498.0000 | 111,000,000 | 10.44% | 0.00% |
| May 12, 2025 | DELANEY MARK E | SVP & Chief Commercial Officer | S | Common Stock | 874 | $175.72 | 8,372.0000 | 111,000,000 | 9.45% | 0.00% |
| April 21, 2025 | Gregg Vicky B | Director | A | Common Stock | 68 | $164.42 | 16,935.0000 | 111,000,000 | 0.40% | 0.00% |
| April 21, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | L | Common Stock | 27 | $164.42 | 12,590.0000 | 111,000,000 | 0.21% | 0.00% |
| April 21, 2025 | SAMAD SAM | Executive Vice President & CFO | L | Common Stock | 74 | $164.42 | 26,451.0000 | 111,000,000 | 0.28% | 0.00% |
| April 21, 2025 | DELANEY MARK E | SVP & Chief Commercial Officer | L | Common Stock | 25 | $164.42 | 9,246.0000 | 111,000,000 | 0.27% | 0.00% |
| April 21, 2025 | Plewman Patrick | SVP for Diagnostic Services | L | Common Stock | 81 | $164.42 | 21,087.0000 | 111,000,000 | 0.39% | 0.00% |
| April 2, 2025 | Davis J. E. | CEO and President | S | Common Stock | 4905 | $168.72 | 150,179.0000 | 111,000,000 | 3.16% | 0.00% |
| April 2, 2025 | Davis J. E. | CEO and President | S | Common Stock | 2366 | $168.03 | 164,448.0000 | 111,000,000 | 1.42% | 0.00% |
| April 2, 2025 | Davis J. E. | CEO and President | S | Common Stock | 1411 | $168.76 | 163,037.0000 | 111,000,000 | 0.86% | 0.00% |
| April 2, 2025 | Davis J. E. | CEO and President | S | Common Stock | 704 | $169.63 | 162,333.0000 | 111,000,000 | 0.43% | 0.00% |
| April 2, 2025 | Davis J. E. | CEO and President | S | Common Stock | 7249 | $167.86 | 155,084.0000 | 111,000,000 | 4.47% | 0.01% |
| April 2, 2025 | Davis J. E. | CEO and President | S | Common Stock | 2764 | $169.56 | 147,415.0000 | 111,000,000 | 1.84% | 0.00% |
| April 2, 2025 | Davis J. E. | CEO and President | S | Common Stock | 6950 | $167.86 | 140,465.0000 | 111,000,000 | 4.71% | 0.01% |
| April 2, 2025 | Davis J. E. | CEO and President | S | Common Stock | 5900 | $168.66 | 134,565.0000 | 111,000,000 | 4.20% | 0.01% |
| April 2, 2025 | Davis J. E. | CEO and President | S | Common Stock | 2493 | $169.57 | 132,072.0000 | 111,000,000 | 1.85% | 0.00% |
| April 2, 2025 | Davis J. E. | CEO and President | S | Common Stock | 750 | $167.86 | 131,322.0000 | 111,000,000 | 0.57% | 0.00% |
| April 2, 2025 | Davis J. E. | CEO and President | S | Common Stock | 584 | $168.70 | 130,738.0000 | 111,000,000 | 0.44% | 0.00% |
| April 2, 2025 | Davis J. E. | CEO and President | S | Common Stock | 267 | $169.60 | 130,471.0000 | 111,000,000 | 0.20% | 0.00% |
| April 2, 2025 | Davis J. E. | CEO and President | S | Common Stock | 1493 | $167.88 | 128,978.0000 | 111,000,000 | 1.14% | 0.00% |
| April 2, 2025 | Davis J. E. | CEO and President | S | Common Stock | 902 | $168.79 | 128,076.0000 | 111,000,000 | 0.70% | 0.00% |
| April 2, 2025 | Davis J. E. | CEO and President | S | Common Stock | 453 | $169.63 | 127,623.0000 | 111,000,000 | 0.35% | 0.00% |
| April 2, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S | Common Stock | 2555 | $170.00 | 12,546.0000 | 111,000,000 | 16.92% | 0.00% |
| April 1, 2025 | Lassiter Wright III | Director | A | Phantom Stock Units | 169 | $0.00 | 359.9110 | 111,000,000 | 88.52% | 0.00% |
| April 1, 2025 | RING TIMOTHY M | Director | A | Phantom Stock Units | 251 | $0.00 | 16,409.5620 | 111,000,000 | 1.55% | 0.00% |
| March 26, 2025 | Plewman Patrick | SVP for Diagnostic Services | F | Common Stock | 162 | $166.71 | 20,988.0000 | 111,000,000 | 0.77% | 0.00% |
| March 26, 2025 | DELANEY MARK E | SVP & Chief Commercial Officer | F | Common Stock | 256 | $166.71 | 9,221.0000 | 111,000,000 | 2.70% | 0.00% |
| March 17, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | Common Stock | 4643 | $170.00 | 43,758.0000 | 111,000,000 | 9.59% | 0.00% |
| March 5, 2025 | Doherty Catherine T. | EVP, Regional Businesses | S | Common Stock | 5370 | $174.13 | 72,495.0000 | 111,000,000 | 6.90% | 0.00% |
| March 4, 2025 | Doherty Catherine T. | EVP, Regional Businesses | A | Common Stock | 10380 | $173.74 | 82,875.0000 | 111,000,000 | 14.32% | 0.01% |
| March 4, 2025 | Doherty Catherine T. | EVP, Regional Businesses | F | Common Stock | 5010 | $173.74 | 77,865.0000 | 111,000,000 | 6.05% | 0.00% |
| March 3, 2025 | Davis J. E. | CEO and President | F | Common Stock | 1662 | $173.74 | 136,553.0000 | 111,000,000 | 1.20% | 0.00% |
| March 4, 2025 | Davis J. E. | CEO and President | A | Common Stock | 61917 | $173.74 | 198,470.0000 | 111,000,000 | 45.34% | 0.06% |
| March 4, 2025 | Davis J. E. | CEO and President | F | Common Stock | 31656 | $173.74 | 166,814.0000 | 111,000,000 | 15.95% | 0.03% |
| March 3, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | F | Common Stock | 992 | $173.74 | 12,516.0000 | 111,000,000 | 7.34% | 0.00% |
| March 4, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A | Common Stock | 4434 | $173.74 | 16,950.0000 | 111,000,000 | 35.43% | 0.00% |
| March 4, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | F | Common Stock | 1879 | $173.74 | 15,071.0000 | 111,000,000 | 11.09% | 0.00% |
| March 3, 2025 | Plewman Patrick | SVP for Diagnostic Services | F | Common Stock | 106 | $173.74 | 17,756.0000 | 111,000,000 | 0.59% | 0.00% |
| March 4, 2025 | Plewman Patrick | SVP for Diagnostic Services | A | Common Stock | 5674 | $173.74 | 23,430.0000 | 111,000,000 | 31.96% | 0.01% |
| March 4, 2025 | Plewman Patrick | SVP for Diagnostic Services | F | Common Stock | 2280 | $173.74 | 21,150.0000 | 111,000,000 | 9.73% | 0.00% |
| March 3, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | F | Common Stock | 322 | $173.74 | 44,349.0000 | 111,000,000 | 0.72% | 0.00% |
| March 4, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | Common Stock | 592 | $175.79 | 43,757.0000 | 111,000,000 | 1.33% | 0.00% |
| March 4, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | A | Common Stock | 8549 | $173.74 | 52,306.0000 | 111,000,000 | 19.54% | 0.01% |
| March 4, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | F | Common Stock | 3906 | $173.74 | 48,400.0000 | 111,000,000 | 7.47% | 0.00% |
| March 4, 2025 | DELANEY MARK E | SVP & Chief Commercial Officer | A | Common Stock | 5317 | $173.74 | 11,300.0000 | 111,000,000 | 88.87% | 0.00% |
| March 4, 2025 | DELANEY MARK E | SVP & Chief Commercial Officer | F | Common Stock | 1823 | $173.74 | 9,477.0000 | 111,000,000 | 16.13% | 0.00% |
| March 4, 2025 | SAMAD SAM | Executive Vice President & CFO | F | Common Stock | 7684 | $173.74 | 26,377.0000 | 111,000,000 | 22.56% | 0.01% |
| March 4, 2025 | SAMAD SAM | Executive Vice President & CFO | A | Common Stock | 13884 | $173.74 | 34,061.0000 | 111,000,000 | 68.81% | 0.01% |
| March 3, 2025 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | F | Common Stock | 1692 | $173.74 | 34,215.0000 | 111,000,000 | 4.71% | 0.00% |
| March 4, 2025 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | A | Common Stock | 1711 | $173.74 | 35,926.0000 | 111,000,000 | 5.00% | 0.00% |
| March 4, 2025 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | F | Common Stock | 867 | $173.74 | 35,059.0000 | 111,000,000 | 2.41% | 0.00% |
| March 3, 2025 | Doherty Catherine T. | EVP, Regional Businesses | F | Common Stock | 394 | $173.74 | 73,211.0000 | 111,000,000 | 0.54% | 0.00% |
| March 4, 2025 | Doherty Catherine T. | EVP, Regional Businesses | S | Common Stock | 716 | $175.79 | 72,495.0000 | 111,000,000 | 0.98% | 0.00% |
| Feb. 26, 2025 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | F | Common Stock | 88 | $171.75 | 35,906.0000 | 111,000,000 | 0.24% | 0.00% |
| Feb. 26, 2025 | SAMAD SAM | Executive Vice President & CFO | F | Common Stock | 869 | $171.75 | 20,177.0000 | 111,000,000 | 4.13% | 0.00% |
| Feb. 26, 2025 | Davis J. E. | CEO and President | F | Common Stock | 2966 | $171.75 | 138,215.0000 | 111,000,000 | 2.10% | 0.00% |
| Feb. 26, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | F | Common Stock | 286 | $171.75 | 45,200.0000 | 111,000,000 | 0.63% | 0.00% |
| Feb. 27, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | Common Stock | 528 | $172.61 | 44,672.0000 | 111,000,000 | 1.17% | 0.00% |
| Feb. 26, 2025 | Plewman Patrick | SVP for Diagnostic Services | F | Common Stock | 229 | $171.75 | 17,853.0000 | 111,000,000 | 1.27% | 0.00% |
| Feb. 26, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | F | Common Stock | 233 | $171.75 | 13,495.0000 | 111,000,000 | 1.70% | 0.00% |
| Feb. 26, 2025 | Doherty Catherine T. | EVP, Regional Businesses | F | Common Stock | 455 | $171.75 | 74,430.0000 | 111,000,000 | 0.61% | 0.00% |
| Feb. 27, 2025 | Doherty Catherine T. | EVP, Regional Businesses | S | Common Stock | 824 | $172.61 | 73,606.0000 | 111,000,000 | 1.11% | 0.00% |
| Feb. 26, 2025 | DELANEY MARK E | SVP & Chief Commercial Officer | F | Common Stock | 214 | $171.75 | 5,983.0000 | 111,000,000 | 3.45% | 0.00% |
| Feb. 20, 2025 | Doherty Catherine T. | EVP, Regional Businesses | S | Common Stock | 899 | $170.99 | 74,885.0000 | 111,000,000 | 1.19% | 0.00% |
| Feb. 19, 2025 | SAMAD SAM | Executive Vice President & CFO | F | Common Stock | 1031 | $169.71 | 21,046.0000 | 111,000,000 | 4.67% | 0.00% |
| Feb. 19, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | F | Common Stock | 374 | $169.71 | 46,090.0000 | 111,000,000 | 0.80% | 0.00% |
| Feb. 20, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | Common Stock | 604 | $170.99 | 45,486.0000 | 111,000,000 | 1.31% | 0.00% |
| Feb. 19, 2025 | Plewman Patrick | SVP for Diagnostic Services | S | Common Stock | 320 | $169.71 | 18,082.0000 | 111,000,000 | 1.74% | 0.00% |
| Feb. 19, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | F | Common Stock | 287 | $169.71 | 13,728.0000 | 111,000,000 | 2.05% | 0.00% |
| Feb. 19, 2025 | Doherty Catherine T. | EVP, Regional Businesses | S | Common Stock | 535 | $169.71 | 75,784.0000 | 111,000,000 | 0.70% | 0.00% |
| Feb. 19, 2025 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | F | Common Stock | 99 | $169.71 | 35,994.0000 | 111,000,000 | 0.27% | 0.00% |
| Feb. 19, 2025 | DELANEY MARK E | SVP & Chief Commercial Officer | F | Common Stock | 242 | $169.71 | 6,197.0000 | 111,000,000 | 3.76% | 0.00% |
| Feb. 19, 2025 | Davis J. E. | CEO and President | F | Common Stock | 2936 | $169.71 | 141,181.0000 | 111,000,000 | 2.04% | 0.00% |
| Feb. 12, 2025 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | A | Non-Qualifed Stock Option (right to buy) | 1738 | $0.00 | 1,738.0000 | 111,000,000 | 9999.99% | 0.00% |
| Feb. 12, 2025 | Davis J. E. | CEO and President | A | Common Stock | 18149 | $0.00 | 144,117.0000 | 111,000,000 | 14.41% | 0.02% |
| Feb. 12, 2025 | Davis J. E. | CEO and President | A | Non-Qualifed Stock Option (right to buy) | 69633 | $0.00 | 69,633.0000 | 111,000,000 | 9999.99% | 0.06% |
| Feb. 12, 2025 | SAMAD SAM | Executive Vice President & CFO | A | Common Stock | 4538 | $0.00 | 22,077.0000 | 111,000,000 | 25.87% | 0.00% |
| Feb. 12, 2025 | SAMAD SAM | Executive Vice President & CFO | A | Non-Qualifed Stock Option (right to buy) | 17403 | $0.00 | 17,403.0000 | 111,000,000 | 9999.99% | 0.02% |
| Feb. 12, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | A | Common Stock | 2345 | $0.00 | 46,467.0000 | 111,000,000 | 5.31% | 0.00% |
| Feb. 12, 2025 | PREVOZNIK MICHAEL E | SVP & General Counsel | A | Non-Qualifed Stock Option (right to buy) | 8991 | $0.00 | 8,991.0000 | 111,000,000 | 9999.99% | 0.01% |
| Feb. 12, 2025 | Plewman Patrick | SVP for Diagnostic Services | A | Common Stock | 2042 | $0.00 | 18,402.0000 | 111,000,000 | 12.48% | 0.00% |
| Feb. 12, 2025 | Plewman Patrick | SVP for Diagnostic Services | A | Non-Qualifed Stock Option (right to buy) | 7833 | $0.00 | 7,833.0000 | 111,000,000 | 9999.99% | 0.01% |
| Feb. 12, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A | Common Stock | 2269 | $0.00 | 14,012.0000 | 111,000,000 | 19.32% | 0.00% |
| Feb. 12, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A | Non-Qualifed Stock Option (right to buy) | 8702 | $0.00 | 8,702.0000 | 111,000,000 | 9999.99% | 0.01% |
| Feb. 12, 2025 | Doherty Catherine T. | EVP, Regional Businesses | A | Common Stock | 3479 | $0.00 | 76,321.0000 | 111,000,000 | 4.78% | 0.00% |
| Feb. 12, 2025 | Doherty Catherine T. | EVP, Regional Businesses | A | Non-Qualifed Stock Option (right to buy) | 13344 | $0.00 | 13,344.0000 | 111,000,000 | 9999.99% | 0.01% |
| Feb. 12, 2025 | DELANEY MARK E | SVP & Chief Commercial Officer | A | Common Stock | 1815 | $0.00 | 6,439.0000 | 111,000,000 | 39.25% | 0.00% |
| Feb. 12, 2025 | DELANEY MARK E | SVP & Chief Commercial Officer | A | Non-Qualifed Stock Option (right to buy) | 6960 | $0.00 | 6,960.0000 | 111,000,000 | 9999.99% | 0.01% |
| Feb. 12, 2025 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | A | Common Stock | 454 | $0.00 | 36,093.0000 | 111,000,000 | 1.27% | 0.00% |
| Feb. 5, 2025 | Gregg Vicky B | Director | S | Common Stock | 1250 | $164.57 | 16,867.0000 | 111,000,000 | 6.90% | 0.00% |
| Feb. 5, 2025 | DELANEY MARK E | SVP & Chief Commercial Officer | S | Common Stock | 403 | $164.30 | 4,624.0000 | 111,000,000 | 8.02% | 0.00% |
| Jan. 29, 2025 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | L | Common Stock | 12 | $158.03 | 11,723.0000 | 111,000,000 | 0.10% | 0.00% |
| Jan. 29, 2025 | Gregg Vicky B | Director | L | Common Stock | 72 | $158.04 | 18,117.0000 | 111,000,000 | 0.40% | 0.00% |
| Jan. 29, 2025 | SAMAD SAM | Executive Vice President & CFO | L | Common Stock | 35 | $158.04 | 17,539.0000 | 111,000,000 | 0.20% | 0.00% |
| Jan. 29, 2025 | Plewman Patrick | SVP for Diagnostic Services | L | Common Stock | 57 | $158.04 | 16,345.0000 | 111,000,000 | 0.35% | 0.00% |
| Jan. 29, 2025 | DELANEY MARK E | SVP & Chief Commercial Officer | L | Common Stock | 4 | $158.03 | 5,027.0000 | 111,000,000 | 0.08% | 0.00% |
| Jan. 2, 2025 | Lassiter Wright III | Director | A | Phantom Stock Units | 190 | $0.00 | 190.0000 | 111,000,000 | 9999.99% | 0.00% |
| Jan. 2, 2025 | RING TIMOTHY M | Director | A | Phantom Stock Units | 281 | $0.00 | 16,081.4140 | 111,000,000 | 1.78% | 0.00% |
| Nov. 29, 2024 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | Common Stock | 3009 | $162.26 | 76,233.0000 | 112,000,000 | 3.80% | 0.00% |
| Nov. 29, 2024 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | Common Stock | 32137 | $163.15 | 44,096.0000 | 112,000,000 | 42.16% | 0.03% |
| Nov. 29, 2024 | PREVOZNIK MICHAEL E | SVP & General Counsel | M | Non-Qualifed Stock Option (right to buy) | 35146 | $86.63 | 0.0000 | 112,000,000 | 100.00% | 0.03% |
| Nov. 27, 2024 | Doherty Catherine T. | EVP, Regional Businesses | M | Common Stock | 33103 | $103.57 | 105,907.0000 | 112,000,000 | 45.47% | 0.03% |
| Nov. 27, 2024 | Doherty Catherine T. | EVP, Regional Businesses | S | Common Stock | 4803 | $162.14 | 101,104.0000 | 112,000,000 | 4.54% | 0.00% |
| Nov. 27, 2024 | Doherty Catherine T. | EVP, Regional Businesses | M | Non-Qualifed Stock Option (right to buy) | 33103 | $103.57 | 0.0000 | 112,000,000 | 100.00% | 0.03% |
| Nov. 27, 2024 | Doherty Catherine T. | EVP, Regional Businesses | S | Common Stock | 28300 | $163.13 | 72,804.0000 | 112,000,000 | 27.99% | 0.03% |
| Nov. 29, 2024 | PREVOZNIK MICHAEL E | SVP & General Counsel | M | Common Stock | 35146 | $86.63 | 79,242.0000 | 112,000,000 | 79.70% | 0.03% |
| Nov. 6, 2024 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | M | Non-Qualifed Stock Option (right to buy) | 10120 | $66.51 | 0.0000 | 112,000,000 | 100.00% | 0.01% |
| Nov. 6, 2024 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | M | Common Stock | 8635 | $71.17 | 44,267.0000 | 112,000,000 | 24.23% | 0.01% |
| Nov. 6, 2024 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | M | Common Stock | 10120 | $66.51 | 54,387.0000 | 112,000,000 | 22.86% | 0.01% |
| Nov. 6, 2024 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | S | Common Stock | 2100 | $152.70 | 52,287.0000 | 112,000,000 | 3.86% | 0.00% |
| Nov. 6, 2024 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | S | Common Stock | 2400 | $153.98 | 49,887.0000 | 112,000,000 | 4.59% | 0.00% |
| Nov. 6, 2024 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | S | Common Stock | 4135 | $154.74 | 45,752.0000 | 112,000,000 | 8.29% | 0.00% |
| Nov. 6, 2024 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | S | Common Stock | 2600 | $152.71 | 43,152.0000 | 112,000,000 | 5.68% | 0.00% |
| Nov. 6, 2024 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | S | Common Stock | 2331 | $154.03 | 40,821.0000 | 112,000,000 | 5.40% | 0.00% |
| Nov. 6, 2024 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | M | Non-Qualifed Stock Option (right to buy) | 8635 | $71.17 | 0.0000 | 112,000,000 | 100.00% | 0.01% |
| Nov. 6, 2024 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | S | Common Stock | 5189 | $154.74 | 35,632.0000 | 112,000,000 | 12.71% | 0.00% |
| Oct. 28, 2024 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S | Common Stock | 1775 | $156.92 | 11,656.0000 | 112,000,000 | 13.22% | 0.00% |
| Oct. 21, 2024 | SAMAD SAM | Executive Vice President & CFO | L | Common Stock | 37 | $149.37 | 17,504.0000 | 112,000,000 | 0.21% | 0.00% |
| Oct. 21, 2024 | Plewman Patrick | SVP for Diagnostic Services | L | Common Stock | 60 | $149.37 | 16,258.0000 | 112,000,000 | 0.37% | 0.00% |
| Oct. 21, 2024 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | L | Common Stock | 21 | $149.37 | 13,432.0000 | 112,000,000 | 0.16% | 0.00% |
| Oct. 21, 2024 | DELANEY MARK E | SVP & Chief Commercial Officer | L | Common Stock | 4 | $149.39 | 5,023.0000 | 112,000,000 | 0.08% | 0.00% |
| Oct. 21, 2024 | Gregg Vicky B | Director | L | Common Stock | 76 | $149.37 | 18,045.0000 | 112,000,000 | 0.42% | 0.00% |
| Oct. 1, 2024 | RING TIMOTHY M | Director | A | Phantom Stock Units | 275 | $0.00 | 15,720.8940 | 112,000,000 | 1.78% | 0.00% |
| Sept. 24, 2024 | GARDNER MARK A | SVP of Molecular Gen & Oncol | F | Common Stock | 120 | $155.70 | 4,673.0000 | 111,000,000 | 2.50% | 0.00% |
| Aug. 29, 2024 | PREVOZNIK MICHAEL E | SVP & General Counsel | M | Common Stock | 32551 | $95.80 | 76,621.0000 | 111,000,000 | 73.86% | 0.03% |
| Aug. 29, 2024 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | Common Stock | 32551 | $154.97 | 44,070.0000 | 111,000,000 | 42.48% | 0.03% |
| Aug. 29, 2024 | PREVOZNIK MICHAEL E | SVP & General Counsel | M | Non-Qualifed Stock Option (right to buy) | 32551 | $95.80 | 0.0000 | 111,000,000 | 100.00% | 0.03% |
| Aug. 28, 2024 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S | Common Stock | 1990 | $153.26 | 13,373.0000 | 111,000,000 | 12.95% | 0.00% |
| Aug. 14, 2024 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | F | Common Stock | 74 | $149.46 | 15,364.0000 | 111,000,000 | 0.48% | 0.00% |
| July 22, 2024 | Plewman Patrick | SVP for Diagnostic Services | L | Common Stock | 60 | $146.97 | 16,162.0000 | 111,000,000 | 0.37% | 0.00% |
| July 22, 2024 | DELANEY MARK E | SVP & Chief Commercial Officer | L | Common Stock | 6 | $146.98 | 5,439.0000 | 111,000,000 | 0.11% | 0.00% |
| July 24, 2024 | DELANEY MARK E | SVP & Chief Commercial Officer | S | Common Stock | 420 | $143.08 | 5,019.0000 | 111,000,000 | 7.72% | 0.00% |
| July 22, 2024 | SAMAD SAM | Executive Vice President & CFO | L | Common Stock | 21 | $146.97 | 17,467.0000 | 111,000,000 | 0.12% | 0.00% |
| July 22, 2024 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | L | Common Stock | 31 | $146.97 | 15,426.0000 | 111,000,000 | 0.20% | 0.00% |
| July 22, 2024 | Gregg Vicky B | Director | L | Common Stock | 77 | $146.97 | 17,969.0000 | 111,000,000 | 0.43% | 0.00% |
| July 16, 2024 | SAMAD SAM | Executive Vice President & CFO | F | Common Stock | 3910 | $142.65 | 17,446.0000 | 111,000,000 | 18.31% | 0.00% |
| July 1, 2024 | RING TIMOTHY M | Director | A | Phantom Stock Units | 308 | $0.00 | 15,367.4490 | 111,000,000 | 2.05% | 0.00% |
| May 16, 2024 | Lassiter Wright III | Director | A | Common Stock | 1482 | $0.00 | 7,709.0000 | 111,000,000 | 23.80% | 0.00% |
| May 16, 2024 | CARTER ROBERT B | Director | A | Common Stock | 1482 | $0.00 | 1,482.0000 | 111,000,000 | 9999.99% | 0.00% |
| May 16, 2024 | PFEIFFER GARY M | Director | A | Common Stock | 1482 | $0.00 | 28,916.0000 | 111,000,000 | 5.40% | 0.00% |
| May 16, 2024 | RING TIMOTHY M | Director | A | Common Stock | 1482 | $0.00 | 27,798.0000 | 111,000,000 | 5.63% | 0.00% |
| May 16, 2024 | MAIN TIMOTHY L | Director | A | Common Stock | 1482 | $0.00 | 25,094.0000 | 111,000,000 | 6.28% | 0.00% |
| May 16, 2024 | MORRISON DENISE M | Director | A | Common Stock | 1482 | $0.00 | 9,490.0000 | 111,000,000 | 18.51% | 0.00% |
| May 16, 2024 | Gregg Vicky B | Director | A | Common Stock | 1482 | $0.00 | 17,892.0000 | 111,000,000 | 9.03% | 0.00% |
| May 16, 2024 | Doi Tracey | Director | A | Common Stock | 1482 | $0.00 | 5,183.0000 | 111,000,000 | 40.04% | 0.00% |
| May 16, 2024 | Diaz Luis | Director | A | Common Stock | 1482 | $0.00 | 2,851.0000 | 111,000,000 | 108.25% | 0.00% |
| April 29, 2024 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S | Common Stock | 1760 | $140.00 | 15,344.0000 | 111,000,000 | 10.29% | 0.00% |
| April 22, 2024 | Gregg Vicky B | Director | A | Common Stock | 81 | $126.24 | 16,410.0000 | 111,000,000 | 0.50% | 0.00% |
| April 22, 2024 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A | Common Stock | 45 | $126.25 | 17,104.0000 | 111,000,000 | 0.26% | 0.00% |
| April 22, 2024 | Plewman Patrick | SVP for Diagnostic Services | A | Common Stock | 69 | $126.25 | 16,062.0000 | 111,000,000 | 0.43% | 0.00% |
| April 22, 2024 | SAMAD SAM | Executive Vice President & CFO | A | Common Stock | 24 | $126.25 | 21,356.0000 | 111,000,000 | 0.11% | 0.00% |
| April 1, 2024 | RING TIMOTHY M | Director | A | Phantom Stock Units | 311 | $0.00 | 14,972.8970 | 111,000,000 | 2.12% | 0.00% |
| March 26, 2024 | Plewman Patrick | SVP for Diagnostic Services | F | Common Stock | 114 | $128.11 | 15,981.0000 | 111,000,000 | 0.71% | 0.00% |
| March 26, 2024 | DELANEY MARK E | SVP & Chief Commercial Officer | F | Common Stock | 170 | $128.11 | 5,433.0000 | 111,000,000 | 3.03% | 0.00% |
| Feb. 28, 2024 | SAMAD SAM | Executive Vice President & CFO | F | Common Stock | 656 | $126.36 | 21,332.0000 | 111,000,000 | 2.98% | 0.00% |
| Feb. 28, 2024 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | F | Common Stock | 68 | $126.36 | 16,995.0000 | 111,000,000 | 0.40% | 0.00% |
| Feb. 28, 2024 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | F | Common Stock | 205 | $126.36 | 17,063.0000 | 111,000,000 | 1.19% | 0.00% |
| Feb. 29, 2024 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | Common Stock | 5611 | $125.88 | 44,019.0000 | 111,000,000 | 11.31% | 0.01% |
| Feb. 28, 2024 | PREVOZNIK MICHAEL E | SVP & General Counsel | F | Common Stock | 456 | $126.36 | 49,630.0000 | 111,000,000 | 0.91% | 0.00% |
| Feb. 28, 2024 | PREVOZNIK MICHAEL E | SVP & General Counsel | F | Common Stock | 405 | $126.36 | 50,086.0000 | 111,000,000 | 0.80% | 0.00% |
| Feb. 29, 2024 | Doherty Catherine T. | EVP, Regional Businesses | S | Common Stock | 1187 | $125.88 | 72,761.0000 | 111,000,000 | 1.61% | 0.00% |
| Feb. 28, 2024 | Doherty Catherine T. | EVP, Regional Businesses | S | Common Stock | 5557 | $126.57 | 73,948.0000 | 111,000,000 | 6.99% | 0.01% |
| Feb. 28, 2024 | Doherty Catherine T. | EVP, Regional Businesses | F | Common Stock | 557 | $126.36 | 79,505.0000 | 111,000,000 | 0.70% | 0.00% |
| Feb. 28, 2024 | Doherty Catherine T. | EVP, Regional Businesses | F | Common Stock | 644 | $126.36 | 80,062.0000 | 111,000,000 | 0.80% | 0.00% |
| Feb. 28, 2024 | Plewman Patrick | SVP for Diagnostic Services | F | Common Stock | 105 | $126.36 | 16,082.0000 | 111,000,000 | 0.65% | 0.00% |
| Feb. 28, 2024 | Plewman Patrick | SVP for Diagnostic Services | F | Common Stock | 228 | $126.36 | 16,187.0000 | 111,000,000 | 1.39% | 0.00% |
| Feb. 28, 2024 | DELANEY MARK E | SVP & Chief Commercial Officer | F | Common Stock | 225 | $126.36 | 5,603.0000 | 111,000,000 | 3.86% | 0.00% |
| Feb. 28, 2024 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | F | Common Stock | 57 | $126.36 | 35,612.0000 | 111,000,000 | 0.16% | 0.00% |
| Feb. 28, 2024 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | F | Common Stock | 52 | $126.36 | 35,669.0000 | 111,000,000 | 0.15% | 0.00% |
| Feb. 28, 2024 | GARDNER MARK A | SVP of Molecular Gen & Oncol | F | Common Stock | 262 | $126.36 | 4,793.0000 | 111,000,000 | 5.18% | 0.00% |
| Feb. 28, 2024 | Davis J. E. | CEO and President | F | Common Stock | 1804 | $126.36 | 125,968.0000 | 111,000,000 | 1.41% | 0.00% |
| Feb. 28, 2024 | Davis J. E. | CEO and President | F | Common Stock | 3216 | $126.36 | 127,772.0000 | 111,000,000 | 2.46% | 0.00% |
| Feb. 23, 2024 | PREVOZNIK MICHAEL E | SVP & General Counsel | A | Common Stock | 7569 | $125.02 | 53,316.0000 | 111,000,000 | 16.55% | 0.01% |
| Feb. 23, 2024 | Davis J. E. | CEO and President | F | Common Stock | 6525 | $125.02 | 130,988.0000 | 111,000,000 | 4.75% | 0.01% |
| Feb. 23, 2024 | Davis J. E. | CEO and President | A | Common Stock | 13390 | $125.02 | 137,513.0000 | 111,000,000 | 10.79% | 0.01% |
| Feb. 23, 2024 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | F | Common Stock | 631 | $125.02 | 35,720.0000 | 111,000,000 | 1.74% | 0.00% |
| Feb. 23, 2024 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | A | Common Stock | 1689 | $125.02 | 36,351.0000 | 111,000,000 | 4.87% | 0.00% |
| Feb. 23, 2024 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | F | Common Stock | 619 | $125.02 | 17,268.0000 | 111,000,000 | 3.46% | 0.00% |
| Feb. 23, 2024 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A | Common Stock | 2039 | $125.02 | 17,887.0000 | 111,000,000 | 12.87% | 0.00% |
| Feb. 23, 2024 | Doherty Catherine T. | EVP, Regional Businesses | F | Common Stock | 3757 | $125.02 | 80,706.0000 | 111,000,000 | 4.45% | 0.00% |
| Feb. 23, 2024 | Doherty Catherine T. | EVP, Regional Businesses | A | Common Stock | 9314 | $125.02 | 84,463.0000 | 111,000,000 | 12.39% | 0.01% |
| Feb. 23, 2024 | Plewman Patrick | SVP for Diagnostic Services | F | Common Stock | 869 | $125.02 | 16,415.0000 | 111,000,000 | 5.03% | 0.00% |
| Feb. 23, 2024 | Plewman Patrick | SVP for Diagnostic Services | A | Common Stock | 2388 | $125.02 | 17,284.0000 | 111,000,000 | 16.03% | 0.00% |
| Feb. 23, 2024 | PREVOZNIK MICHAEL E | SVP & General Counsel | F | Common Stock | 2825 | $125.02 | 50,491.0000 | 111,000,000 | 5.30% | 0.00% |
| Feb. 22, 2024 | PREVOZNIK MICHAEL E | SVP & General Counsel | S | Common Stock | 661 | $126.14 | 45,747.0000 | 111,000,000 | 1.42% | 0.00% |
| Feb. 21, 2024 | Davis J. E. | CEO and President | F | Common Stock | 762 | $125.02 | 124,123.0000 | 111,000,000 | 0.61% | 0.00% |
| Feb. 21, 2024 | Plewman Patrick | SVP for Diagnostic Services | F | Common Stock | 139 | $125.02 | 14,896.0000 | 111,000,000 | 0.92% | 0.00% |
| Feb. 21, 2024 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | F | Common Stock | 89 | $125.02 | 33,981.0000 | 111,000,000 | 0.26% | 0.00% |
| Feb. 22, 2024 | Doherty Catherine T. | EVP, Regional Businesses | S | Common Stock | 821 | $126.14 | 75,149.0000 | 111,000,000 | 1.08% | 0.00% |
| Feb. 21, 2024 | Doherty Catherine T. | EVP, Regional Businesses | F | Common Stock | 493 | $125.02 | 75,970.0000 | 111,000,000 | 0.64% | 0.00% |
| Feb. 21, 2024 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | F | Common Stock | 102 | $125.02 | 15,848.0000 | 111,000,000 | 0.64% | 0.00% |
| Feb. 23, 2024 | Gregg Vicky B | Director | S | Common Stock | 2500 | $126.64 | 16,329.0000 | 111,000,000 | 13.28% | 0.00% |
| Feb. 21, 2024 | PREVOZNIK MICHAEL E | SVP & General Counsel | F | Common Stock | 407 | $125.02 | 46,408.0000 | 111,000,000 | 0.87% | 0.00% |
| Feb. 14, 2024 | DELANEY MARK E | SVP & Chief Commercial Officer | A | Common Stock | 2348 | $0.00 | 5,828.0000 | 111,000,000 | 67.47% | 0.00% |
| Feb. 14, 2024 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A | Common Stock | 2641 | $0.00 | 15,945.0000 | 111,000,000 | 19.85% | 0.00% |
| Feb. 14, 2024 | SAMAD SAM | Executive Vice President & CFO | A | Non-Qualifed Stock Option (right to buy) | 22835 | $0.00 | 22,835.0000 | 111,000,000 | 9999.99% | 0.02% |
| Feb. 14, 2024 | SAMAD SAM | Executive Vice President & CFO | A | Common Stock | 5478 | $0.00 | 21,988.0000 | 111,000,000 | 33.18% | 0.00% |
| Feb. 14, 2024 | PREVOZNIK MICHAEL E | SVP & General Counsel | A | Non-Qualifed Stock Option (right to buy) | 12231 | $0.00 | 12,231.0000 | 111,000,000 | 9999.99% | 0.01% |
| Feb. 14, 2024 | PREVOZNIK MICHAEL E | SVP & General Counsel | A | Common Stock | 2935 | $0.00 | 46,814.0000 | 111,000,000 | 6.69% | 0.00% |
| Feb. 14, 2024 | Plewman Patrick | SVP for Diagnostic Services | A | Non-Qualifed Stock Option (right to buy) | 10190 | $0.00 | 10,190.0000 | 111,000,000 | 9999.99% | 0.01% |
| Feb. 14, 2024 | Plewman Patrick | SVP for Diagnostic Services | A | Common Stock | 2446 | $0.00 | 15,035.0000 | 111,000,000 | 19.43% | 0.00% |
| Feb. 14, 2024 | GARDNER MARK A | SVP of Molecular Gen & Oncol | A | Non-Qualifed Stock Option (right to buy) | 9376 | $0.00 | 9,376.0000 | 111,000,000 | 9999.99% | 0.01% |
| Feb. 14, 2024 | GARDNER MARK A | SVP of Molecular Gen & Oncol | A | Common Stock | 2250 | $0.00 | 5,055.0000 | 111,000,000 | 80.21% | 0.00% |
| Feb. 14, 2024 | Davis J. E. | CEO and President | A | Non-Qualifed Stock Option (right to buy) | 92779 | $0.00 | 92,779.0000 | 111,000,000 | 9999.99% | 0.08% |
| Feb. 14, 2024 | Davis J. E. | CEO and President | A | Common Stock | 22251 | $0.00 | 124,885.0000 | 111,000,000 | 21.68% | 0.02% |
| Feb. 14, 2024 | DELANEY MARK E | SVP & Chief Commercial Officer | A | Non-Qualifed Stock Option (right to buy) | 9783 | $0.00 | 9,783.0000 | 111,000,000 | 9999.99% | 0.01% |
| Feb. 14, 2024 | Doherty Catherine T. | SVP, Regional Businesses | A | Common Stock | 4304 | $0.00 | 76,462.0000 | 111,000,000 | 5.96% | 0.00% |
| Feb. 14, 2024 | Doherty Catherine T. | SVP, Regional Businesses | A | Non-Qualifed Stock Option (right to buy) | 17939 | $0.00 | 17,939.0000 | 111,000,000 | 9999.99% | 0.02% |
| Feb. 14, 2024 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | A | Common Stock | 558 | $0.00 | 34,751.0000 | 111,000,000 | 1.63% | 0.00% |
| Feb. 14, 2024 | DEPPE MICHAEL J | SVP, Corp. Controller & CAO | A | Non-Qualifed Stock Option (right to buy) | 2322 | $0.00 | 2,322.0000 | 111,000,000 | 9999.99% | 0.00% |
| Feb. 14, 2024 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A | Non-Qualifed Stock Option (right to buy) | 11007 | $0.00 | 11,007.0000 | 111,000,000 | 9999.99% | 0.01% |
| Jan. 31, 2024 | Gregg Vicky B | Director | A | Common Stock | 88 | $129.33 | 18,829.0000 | 111,000,000 | 0.47% | 0.00% |
| Jan. 31, 2024 | SAMAD SAM | Executive Vice President & CFO | A | Common Stock | 17 | $129.33 | 16,510.0000 | 111,000,000 | 0.10% | 0.00% |
| Jan. 31, 2024 | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A | Common Stock | 29 | $129.33 | 13,298.0000 | 111,000,000 | 0.22% | 0.00% |
| Jan. 31, 2024 | Plewman Patrick | SVP for Diagnostic Services | A | Common Stock | 50 | $129.33 | 12,589.0000 | 111,000,000 | 0.40% | 0.00% |
| May 10, 2023 | PREVOZNIK MICHAEL E | SVP & General Counsel | G | Common Stock | 188 | $0.00 | 43,845.0000 | 111,000,000 | 0.43% | 0.00% |
| Jan. 2, 2024 | RING TIMOTHY M | Director | A | Phantom Stock Units | 294 | $0.00 | 14,581.6540 | 111,000,000 | 2.06% | 0.00% |